{"id":39796,"date":"2025-08-20T20:32:04","date_gmt":"2025-08-20T12:32:04","guid":{"rendered":"https:\/\/flcube.com\/?p=39796"},"modified":"2025-08-20T20:32:05","modified_gmt":"2025-08-20T12:32:05","slug":"santhera-pharmaceuticals-signs-exclusive-agreement-with-uniphar-for-agamree-distribution-in-middle-east","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=39796","title":{"rendered":"Santhera Pharmaceuticals Signs Exclusive Agreement with Uniphar for AGAMREE Distribution in Middle East"},"content":{"rendered":"\n<p>Swiss firm Santhera Pharmaceuticals (<a href=\"https:\/\/www.google.com\/finance\/quote\/SANN:SWX\">SWX: SANN<\/a>), a leader in innovative therapies for rare diseases, has announced the signing of an exclusive agreement with Uniphar to manage the distribution of AGAMREE (vamorolone) in the United Arab Emirates, Saudi Arabia, Kuwait, Oman, and Bahrain. The drug is approved for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older.<\/p>\n\n\n\n<p><strong>Exclusive Distribution Agreement<\/strong><br>Under this agreement, sales of AGAMREE are expected to begin on a named patient basis in Q1 2026, with broader commercial sales anticipated later in 2026 following market authorization and pricing agreements. Santhera will receive a percentage of net sales as payment, consistent with the company&#8217;s previous distribution agreements. This collaboration aims to ensure timely access to this innovative therapy for patients across these Middle Eastern countries.<\/p>\n\n\n\n<p><strong>About Duchenne Muscular Dystrophy (DMD)<\/strong><br>Duchenne muscular dystrophy is a rare X-linked recessive genetic disorder caused by mutations in the muscle dystrophin gene, leading to the loss of muscle dystrophin\u2014a protein critical for maintaining muscle cell membrane stability. AGAMREE, a novel dissociative corticosteroid, offers therapeutic benefits comparable to traditional corticosteroids while providing significant clinical safety advantages, such as maintaining normal bone metabolism, bone density, and growth.<\/p>\n\n\n\n<p><strong>Licensing Deal with Sperogenix Therapeutics<\/strong><br>AGAMREE was licensed by China-based Sperogenix Therapeutics Limited from Santhera in January 2022 under a deal involving an upfront payment of USD 20 million and potential milestone payments totaling USD 104 million. This partnership underscores the global interest in advancing innovative therapies for rare diseases like DMD.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Swiss firm Santhera Pharmaceuticals (SWX: SANN), a leader in innovative therapies for rare diseases, has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":39798,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[24,686,1372],"class_list":["post-39796","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-rare-orphan-disease-drugs","tag-santhera-pharmaceuticals","tag-swx-sann"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Santhera Pharmaceuticals Signs Exclusive Agreement with Uniphar for AGAMREE Distribution in Middle East - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Swiss firm Santhera Pharmaceuticals (SWX: SANN), a leader in innovative therapies for rare diseases, has announced the signing of an exclusive agreement with Uniphar to manage the distribution of AGAMREE (vamorolone) in the United Arab Emirates, Saudi Arabia, Kuwait, Oman, and Bahrain. The drug is approved for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=39796\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Santhera Pharmaceuticals Signs Exclusive Agreement with Uniphar for AGAMREE Distribution in Middle East\" \/>\n<meta property=\"og:description\" content=\"Swiss firm Santhera Pharmaceuticals (SWX: SANN), a leader in innovative therapies for rare diseases, has announced the signing of an exclusive agreement with Uniphar to manage the distribution of AGAMREE (vamorolone) in the United Arab Emirates, Saudi Arabia, Kuwait, Oman, and Bahrain. The drug is approved for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=39796\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-20T12:32:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-20T12:32:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2001-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39796#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39796\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Santhera Pharmaceuticals Signs Exclusive Agreement with Uniphar for AGAMREE Distribution in Middle East\",\"datePublished\":\"2025-08-20T12:32:04+00:00\",\"dateModified\":\"2025-08-20T12:32:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39796\"},\"wordCount\":264,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39796#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2001-1.webp\",\"keywords\":[\"Rare \\\/ orphan disease drugs\",\"Santhera Pharmaceuticals\",\"SWX: SANN\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=39796#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39796\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=39796\",\"name\":\"Santhera Pharmaceuticals Signs Exclusive Agreement with Uniphar for AGAMREE Distribution in Middle East - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39796#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39796#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2001-1.webp\",\"datePublished\":\"2025-08-20T12:32:04+00:00\",\"dateModified\":\"2025-08-20T12:32:05+00:00\",\"description\":\"Swiss firm Santhera Pharmaceuticals (SWX: SANN), a leader in innovative therapies for rare diseases, has announced the signing of an exclusive agreement with Uniphar to manage the distribution of AGAMREE (vamorolone) in the United Arab Emirates, Saudi Arabia, Kuwait, Oman, and Bahrain. The drug is approved for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39796#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=39796\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39796#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2001-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2001-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Santhera Pharmaceuticals Signs Exclusive Agreement with Uniphar for AGAMREE Distribution in Middle East\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39796#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Santhera Pharmaceuticals Signs Exclusive Agreement with Uniphar for AGAMREE Distribution in Middle East\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Santhera Pharmaceuticals Signs Exclusive Agreement with Uniphar for AGAMREE Distribution in Middle East - Insight, China&#039;s Pharmaceutical Industry","description":"Swiss firm Santhera Pharmaceuticals (SWX: SANN), a leader in innovative therapies for rare diseases, has announced the signing of an exclusive agreement with Uniphar to manage the distribution of AGAMREE (vamorolone) in the United Arab Emirates, Saudi Arabia, Kuwait, Oman, and Bahrain. The drug is approved for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=39796","og_locale":"en_US","og_type":"article","og_title":"Santhera Pharmaceuticals Signs Exclusive Agreement with Uniphar for AGAMREE Distribution in Middle East","og_description":"Swiss firm Santhera Pharmaceuticals (SWX: SANN), a leader in innovative therapies for rare diseases, has announced the signing of an exclusive agreement with Uniphar to manage the distribution of AGAMREE (vamorolone) in the United Arab Emirates, Saudi Arabia, Kuwait, Oman, and Bahrain. The drug is approved for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older.","og_url":"https:\/\/flcube.com\/?p=39796","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-20T12:32:04+00:00","article_modified_time":"2025-08-20T12:32:05+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2001-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=39796#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=39796"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Santhera Pharmaceuticals Signs Exclusive Agreement with Uniphar for AGAMREE Distribution in Middle East","datePublished":"2025-08-20T12:32:04+00:00","dateModified":"2025-08-20T12:32:05+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=39796"},"wordCount":264,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=39796#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2001-1.webp","keywords":["Rare \/ orphan disease drugs","Santhera Pharmaceuticals","SWX: SANN"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=39796#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=39796","url":"https:\/\/flcube.com\/?p=39796","name":"Santhera Pharmaceuticals Signs Exclusive Agreement with Uniphar for AGAMREE Distribution in Middle East - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=39796#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=39796#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2001-1.webp","datePublished":"2025-08-20T12:32:04+00:00","dateModified":"2025-08-20T12:32:05+00:00","description":"Swiss firm Santhera Pharmaceuticals (SWX: SANN), a leader in innovative therapies for rare diseases, has announced the signing of an exclusive agreement with Uniphar to manage the distribution of AGAMREE (vamorolone) in the United Arab Emirates, Saudi Arabia, Kuwait, Oman, and Bahrain. The drug is approved for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=39796#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=39796"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=39796#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2001-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2001-1.webp","width":1080,"height":608,"caption":"Santhera Pharmaceuticals Signs Exclusive Agreement with Uniphar for AGAMREE Distribution in Middle East"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=39796#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Santhera Pharmaceuticals Signs Exclusive Agreement with Uniphar for AGAMREE Distribution in Middle East"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2001-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39796","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=39796"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39796\/revisions"}],"predecessor-version":[{"id":39799,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39796\/revisions\/39799"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/39798"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=39796"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=39796"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=39796"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}